Accès gratuit
Méd. Intensive Réa.
Volume 26, Numéro 3, Mai 2017
Page(s) 218 - 223
Section Mise au point / Update
Publié en ligne 21 mars 2017
  • Patterson TF, Thompson GR3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE, (2016) Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63: e1–e60 [CrossRef] [PubMed] [Google Scholar]
  • Lass-Florl C, (2011) Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 71: 2405–2419 [CrossRef] [PubMed] [Google Scholar]
  • Shirley M, Scott LJ, (2016) Isavuconazole: a review in invasive Aspergillosis and Mucormycosis. Drugs 76: 1647–1657 [CrossRef] [PubMed] [Google Scholar]
  • Nett JE, Andes DR, (2012) Antifungals: properties and clinical use. In: Calderone RA, Clancy CJ (eds) Candida and candidiasis. ASM Press, Washington, DC, pp 345–371 [CrossRef] [Google Scholar]
  • Miceli MH, Kauffman CA, (2015) Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 61: 1558–1565 [CrossRef] [PubMed] [Google Scholar]
  • Sanglard D, Odds FC, (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73–85 [CrossRef] [PubMed] [Google Scholar]
  • Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M, (2013) In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 51: 2608–2616 [CrossRef] [PubMed] [Google Scholar]
  • Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA, (2014) Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 178: 1–9 [CrossRef] [PubMed] [Google Scholar]
  • Thompson GR3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF, (2009) Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53: 309–311 [CrossRef] [PubMed] [Google Scholar]
  • Thompson GR3rd, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF, (2009) In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 64: 79–83 [CrossRef] [PubMed] [Google Scholar]
  • Warn PA, Sharp A, Denning DW, (2006) In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 57: 135–138 [CrossRef] [PubMed] [Google Scholar]
  • Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Florl C, Martin-Mazuelos E, Meis J, Pelaez T, Pfaller MA, Turnidge J, (2013) Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 57: 3823–3828 [CrossRef] [PubMed] [Google Scholar]
  • Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF, (2012) Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the Cyp51A gene in India. J Antimicrob Chemother 67: 362–366 [CrossRef] [PubMed] [Google Scholar]
  • Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ, (2012) Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56: 10–16 [CrossRef] [PubMed] [Google Scholar]
  • Verweij PE, Gonzalez GM, Wiedrhold NP, Lass-Florl C, Warn P, Heep M, Ghannoum MA, Guinea J, (2009) In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J Chemother 21: 272–281 [CrossRef] [PubMed] [Google Scholar]
  • Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C, (2006) Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 mg) and oral administrations (100, 200, and 400 mg) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: 279–285 [CrossRef] [PubMed] [Google Scholar]
  • Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M, (2006) Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: 286–293 [CrossRef] [PubMed] [Google Scholar]
  • Livermore J, Hope W, (2012) Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 8: 759–765 [CrossRef] [PubMed] [Google Scholar]
  • Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ, (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59: 2078–2085 [CrossRef] [PubMed] [Google Scholar]
  • Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL, (2016) Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother 60: 5483–5491 [CrossRef] [PubMed] [Google Scholar]
  • Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA, (2009) Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63: 161–166 [CrossRef] [PubMed] [Google Scholar]
  • Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR, (2013) Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother 57: 5642–5648 [CrossRef] [PubMed] [Google Scholar]
  • Lepak AJ, Marchillo K, Vanhecker J, Andes DR, (2013) Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary Aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 57: 6284–6289 [CrossRef] [PubMed] [Google Scholar]
  • Seyedmousavi S, Bruggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW, (2015) Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother 59: 2855–2866 [CrossRef] [PubMed] [Google Scholar]
  • Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ, (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: 760–769 [CrossRef] [PubMed] [Google Scholar]
  • Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, Franks B, Shorr AF, (2016) Hospital resource use of patients receiving isavuconazole vs. voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ 19: 728–734 [CrossRef] [PubMed] [Google Scholar]
  • Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J, (2017) Cost–effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive Aspergillosis. Adv Ther 34: 207–220 [CrossRef] [PubMed] [Google Scholar]
  • Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JA, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJ, Vital and FungiScope Mucormycosis Investigators, (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16: 828–837 [CrossRef] [PubMed] [Google Scholar]
  • Thompson GR3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR, (2016) Isavuconazole treatment of Cryptococcosis and dimorphic mycoses. Clin Infect Dis 63: 356–362 [CrossRef] [PubMed] [Google Scholar]
  • HAS, (2016). In: Editor (ed) (eds) Book., City, [Google Scholar]
  • Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R, (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 102: 433–444 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.